--- title: "Moleculin Biotech | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295935312.md" datetime: "2026-08-14T12:33:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295935312.md) - [en](https://longbridge.com/en/news/295935312.md) - [zh-HK](https://longbridge.com/zh-HK/news/295935312.md) generator: "portal-rs" --- # Moleculin Biotech | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -1.4. EBIT: As of FY2026 Q2, the actual value is USD -7.483 M. ### Financial Performance for Three Months Ended June 30, 2026 vs. 2025 - **Research and Development Expenses**: Moleculin Biotech, Inc. reported $5.5 million in 2026, an increase from $3.6 million in 2025, primarily due to the MIRACLE clinical trial, additional nonclinical studies, and other research costs. - **General and Administrative Expenses**: These remained consistent at approximately $2.1 million in both 2026 and 2025. - **Depreciation and Amortization**: Depreciation and amortization were $8 thousand in 2026, compared to $29 thousand in 2025. - **Total Operating Expenses**: Total operating expenses increased to $7.6 million in 2026 from $5.7 million in 2025. - **Loss from Operations**: The loss from operations was - $7.6 million in 2026, compared to - $5.7 million in 2025. - **Net Loss**: The net loss significantly improved to - $7.6 million in 2026 from - $17.8 million in 2025. ### Financial Performance for Six Months Ended June 30, 2026 vs. 2025 - **Research and Development Expenses**: Research and development expenses increased to $10.8 million in 2026 from $7.0 million in 2025. - **General and Administrative Expenses**: General and administrative expenses were $4.6 million in both 2026 and 2025. - **Depreciation and Amortization**: Depreciation and amortization were $16 thousand in 2026, compared to $59 thousand in 2025. - **Total Operating Expenses**: Total operating expenses were $15.4 million in 2026, up from $11.7 million in 2025. - **Loss from Operations**: The loss from operations was - $15.4 million in 2026, compared to - $11.7 million in 2025. - **Net Loss**: The net loss improved to - $20.5 million in 2026 from - $23.7 million in 2025. ### Balance Sheet Highlights (as of June 30, 2026 vs. December 31, 2025) - **Cash and Cash Equivalents**: Cash and cash equivalents were $7.3 million as of June 30, 2026, down from $8.9 million as of December 31, 2025. - **Total Current Assets**: Total current assets decreased to $8.7 million as of June 30, 2026, from $9.7 million as of December 31, 2025. - **Total Assets**: Total assets were $21.1 million as of June 30, 2026, a decrease from $22.1 million as of December 31, 2025. - **Total Current Liabilities**: Total current liabilities increased to $9.3 million as of June 30, 2026, from $6.9 million as of December 31, 2025. - **Total Liabilities**: Total liabilities increased to $9.5 million as of June 30, 2026, from $7.1 million as of December 31, 2025. - **Total Stockholders’ Equity**: Total stockholders’ equity decreased to $11.6 million as of June 30, 2026, from $15.0 million as of December 31, 2025. ### Operational Metrics and Company-Specific Indicators - **MIRACLE Trial Efficacy**: Interim data from the Phase 2⁄3 MIRACLE trial showed complete remission (CR) rates of 43% and 36% in Annamycin treatment arms (190 mg/m² and 230 mg/m² plus cytarabine, respectively), compared to 12% for the control arm. Composite complete remission (CRc) reached 50% and 57% in Annamycin cohorts versus 29% for the control arm. - **Cardiotoxicity**: Moleculin Biotech, Inc. reported no detectable cardiotoxicity with Annamycin, even with cumulative exposure levels exceeding conventional anthracycline limits, with this absence continuing to be observed in the MIRACLE trial. - **Enrollment Progress**: Over 80% of the planned 90 patients in Part A of the MIRACLE trial were enrolled as of the interim analysis. - **Pipeline Programs**: Moleculin Biotech, Inc. continues to support development activities for WP1066 through investigator-sponsored and externally funded studies and is also developing the WP1122 portfolio. ### Outlook and Guidance Moleculin Biotech, Inc. anticipates its cash position, including $9.3 million raised after quarter-end, will fund operations into the first quarter of 2027. The company expects to complete enrollment in Part A of the MIRACLE trial by September 2026, with data unblinding for 90 subjects projected between December 2026 and February 2027. Part B of the MIRACLE trial is slated to commence in the first half of 2027, with the goal of initiating a rolling New Drug Application (NDA) submission for accelerated approval in 2028 and completing it in 2029. ### Related Stocks - [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md) ## Related News & Research - [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md) - [Xcel Energy sets BRL 0.26 per unit distribution for payment Oct. 26, 2026](https://longbridge.com/en/news/296646864.md) - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**